Summary of the Conference Call Company and Industry Involved - **Company**: Innovent Biologics (信达生物) - **Partner**: Eli Lilly (礼来制药) - **Industry**: Biopharmaceuticals, specifically focusing on oncology and immunology Core Points and Arguments - **Strategic Collaboration**: Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology [1] - **Development Responsibilities**: Innovent will lead the projects from drug discovery to clinical proof of concept in China, specifically completing Phase II clinical trials [1] - **Global Rights**: Eli Lilly will obtain exclusive global development and commercialization rights outside Greater China, while Innovent retains all rights within Greater China [1] - **Financial Terms**: Innovent will receive an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future achievements [1] - **Sales Revenue Sharing**: Innovent is entitled to a tiered sales revenue share from net sales outside Greater China for each product [2] Additional Important Insights - **Seventh Collaboration**: This marks the seventh collaboration between Innovent and Eli Lilly, indicating a strong ongoing relationship [3] - **Risk Mitigation**: The "China PoC + global development" model reduces Innovent's overseas development risks while leveraging Eli Lilly's global network to enhance efficiency [4] - **Strategic Significance**: The collaboration's financial components will strengthen Innovent's financial security, and the sales revenue sharing will provide long-term benefits from global market growth [5] - **Synergy with Existing Pipeline**: The focus on oncology and immunology aligns with Innovent's existing core pipeline, including products like IBI363 (PD1/IL2) and IBI343 (CLDN18.2 ADC), enhancing overall competitiveness [5] - **Potential Early-Stage Products**: Other early-stage clinical products with significant market potential include IBI324 (VEGF-A/Ang-2), IBI3001 (EGFR/B7H3 ADC), and IBI3002 (IL-4Rα/TSLP) [5]

信达生物(01801)再涨超5%，截至发稿，涨5.56%，报90.1港元，成交额6.03亿港元。 海通国际认为，首付款与里程碑款将强化信达的财务安全垫，销售分成使其长期受益于全球市场增长。 合作聚焦的肿瘤与免疫领域，可与信达现有核心管线，如IBI363(PD1/IL2)、IBI343(CLDN18.2ADC)等 形成协同，提升整体竞争力。高盛则称，考虑到当前市场隐含的加权平均资本成本(12%)较高，认为其 目前股价被低估；予该股"买入"评级；基于风险调整后、现金流量折现法，予目标价102.85港元。 消息面上，信达生物日前宣布与礼来制药达成第七次战略合作，双方将携手推进肿瘤及免疫领域创新药 物的全球研发。根据协议条款，信达生物将直接获得3.5亿美元首付款。基于研发、监管及商业化等多 个节点的达成，信达后续还有资格获得总额最高约85亿美元的里程碑付款，并获得相关产品在大中华区 以外市场的梯度销售分成。据悉，在昨日举行的业务进展更新电话会上，信达生物管理层针对此次高额 交易的底层逻辑、资金流向以及公司全球化战略进行了详细披露。管理层表示，3.5亿美元的首付款将 很快到账，可有效覆盖公司未来的海外临床投入。 ...

Summary of Conference Call Records Industry Overview - The Hang Seng Index increased by 1.5%, the Hang Seng China Enterprises Index rose by 1.2%, and the Hang Seng Tech Index went up by 1.0%, with a total trading volume of HKD 13.6 billion [1][1][1] - Southbound funds recorded a net inflow of USD 164 million [1][1][1] - Leading sectors included materials, which rose by 2.8%, financials up by 2.3%, and healthcare up by 1.9% [1][1][1] - Underperforming sectors were consumer staples and utilities, both up by 0.2%, while telecommunications fell by 1.3% [1][1][1] Market Sentiment - The Hong Kong market showed strong trading performance, with materials and healthcare sectors leading the gains [1][1][1] - Despite low nominal amounts, southbound investors made net purchases, while the CSI 300 Index increased by 1.4%, indicating strong performance [1][1][1] - Trading volumes in Hong Kong and mainland markets were below the 20-day average, suggesting cautious investor sentiment ahead of the upcoming Chinese New Year holiday [1][1][1] - The market's strength was attributed to a technical rebound in the US stock market following three days of sell-off [1][1][1] Sector Performance - In the Asian market, the AI sector performed notably well, while the liquor and banking sectors lagged but still showed gains, with the Goldman Sachs China Liquor Index down by 0.3% and the Goldman Sachs China Banking Index up by 0.3% [2][2][2] - Notable performing sectors included the Goldman Sachs China AI Index, which rose by 5.5%, the AI-generated content index up by 4.9%, and the solar energy index up by 4.5% [2][2][2] - Trading flows indicated a shift towards defensive sectors and "safe haven" assets as investors prepared for the holiday [2][2][2] - The materials sector saw gains due to technical support from base metals following the market rebound [2][2][2] Individual Stock Highlights - Innovent Biologics rose by 5.6% after announcing a strategic partnership with Eli Lilly, marking their largest collaboration to date worth USD 8.5 billion [2][2][2] - Pop Mart International increased by 5.1%, with its founder reporting that Labubu's sales exceeded 10 million units last year, with the stock price reaching HKD 256, breaking a one-month resistance level [2][2][2] - Kuaishou fell by 4.3% due to a fine of CNY 119.1 million imposed by Beijing's internet regulator for failing to curb illegal content dissemination [3][3][3] - Short interest in Kuaishou rose to 7.1% of the float [3][3][3] Underperforming Stocks - Energy and telecommunications stocks lagged, with China Telecom down by 2.4% due to unmet targets last year, and China Mobile down by 1.6% following a downgrade from brokers [4][4][4] - The consumer staples sector also showed poor performance [4][4][4]

智通财经APP获悉，信达生物(01801)再涨超5%，截至发稿，涨5.56%，报90.1港元，成交额6.03亿港 元。 海通国际认为，首付款与里程碑款将强化信达的财务安全垫，销售分成使其长期受益于全球市场增长。 合作聚焦的肿瘤与免疫领域，可与信达现有核心管线，如IBI363（PD1/IL2）、IBI343（CLDN18.2 ADC）等形成协同，提升整体竞争力。高盛则称，考虑到当前市场隐含的加权平均资本成本(12%)较 高，认为其目前股价被低估；予该股"买入"评级；基于风险调整后、现金流量折现法，予目标价102.85 港元。 消息面上，信达生物日前宣布与礼来制药达成第七次战略合作，双方将携手推进肿瘤及免疫领域创新药 物的全球研发。根据协议条款，信达生物将直接获得3.5亿美元首付款。基于研发、监管及商业化等多 个节点的达成，信达后续还有资格获得总额最高约85亿美元的里程碑付款，并获得相关产品在大中华区 以外市场的梯度销售分成。据悉，在昨日举行的业务进展更新电话会上，信达生物管理层针对此次高额 交易的底层逻辑、资金流向以及公司全球化战略进行了详细披露。管理层表示，3.5亿美元的首付款将 很快到账，可有效覆盖公司未来 ...

（2）创新药方面，2~3月为港股药企业绩披露窗口，多家有望迎来减亏或扭亏；展望全年，AACR(4 月)、ASCO(5月)、ESMO(10月)等学术会议渐次到来，国产创新药有望进一步带来临床数据的兑现。 关注港股通科技ETF基金（159101.SZ）及其联接C（025806.OF），被动跟踪国证港股通科技指数，该 指数在恒生科技基础上，龙头权重更集中（阿里巴巴、腾讯控股合计占比30%），同时兼顾创新药龙头 （药明生物/信达生物/康方生物）。港股通科技ETF基金（159101.SZ）在深圳证券交易所上市，并支持 T+0日内灵活回转交易，为A股投资者提供低门槛、免开跨境户和免换汇的便利。 2月10日盘初，港股AI应用、创新药板块延续昨日涨势。阅文集团、智谱涨超6%，快手-W涨超4%，药 明生物、康方生物、信达生物涨超2%，港股通科技ETF基金（159101.SZ）盘中涨1%。 综合招商证券、国金证券等机构观点，港股科技资产前期回调较为充分，后市催化增多： （1）AI应用方面，腾讯、阿里纷纷在春节期间进行大模型宣传、快手可灵年化ARR超预期、DeepSeek 或在春节期间发布最新V4大模型。 ...

Summary of Key Points from Conference Call Records Industry Overview - The reports primarily focus on the Hong Kong market and specific sectors such as materials, healthcare, AI, and telecommunications [1][2][4]. Market Performance - The Hang Seng Index increased by 1.5%, the Hang Seng China Enterprises Index rose by 1.2%, and the Hang Seng Technology Index went up by 1.0%, with a total trading volume of HKD 13.6 billion [1]. - Southbound funds recorded a net inflow of USD 164 million, indicating positive investor sentiment despite lower nominal amounts [1]. - The materials sector led the market with a 2.8% increase, followed by the financial sector at 2.3% and healthcare at 1.9% [1]. Sector Analysis Materials Sector - The materials sector saw a rise due to technical support from base metals following a market rebound [2]. - Notable stock movements included: - Innovent Biologics increased by 5.6% after announcing a strategic partnership with Eli Lilly, valued at USD 8.5 billion, marking their largest collaboration to date [2]. - Pop Mart International rose by 5.1%, with its founder reporting over 10 million units sold of the Labubu product last year [2]. AI Sector - The AI sector performed exceptionally well, with the Goldman Sachs China AI Index up by 5.5% and the AI-generated content index up by 4.9% [2]. Telecommunications Sector - Telecommunications stocks lagged, with China Telecom down by 2.4% due to unmet targets and China Mobile down by 1.6% following a downgrade from brokers [4]. Trading Trends - Overall market sentiment showed a shift towards defensive sectors and "safe haven" assets as investors prepared for the upcoming Chinese New Year holiday [2]. - There was a mixed trading approach in consumer stocks, with purchases in apparel and sales in toy and education technology stocks [2]. Individual Stock Performance - Kuaishou's stock fell by 4.3% due to regulatory penalties amounting to CNY 119.1 million for failing to control illegal content dissemination [3]. - Short interest in Kuaishou increased to 7.1% of its float, indicating growing bearish sentiment [3]. Conclusion - The Hong Kong market displayed resilience with significant sector performances, particularly in materials and AI, while telecommunications and certain consumer sectors faced challenges. The upcoming holiday period is influencing trading strategies, with a cautious approach observed among investors [1][2][4].

Group 1: Market Activity - Hong Kong pharmaceutical stocks remain active, with Innovent Biologics experiencing a significant surge following an $8.85 billion business development deal, rising 5% after a previous 7.42% increase [1][7] - Other companies such as Zai Lab, CSPC Pharmaceutical, and Rongchang Biologics also saw substantial gains [1][7] - The Hong Kong Stock Connect Innovation Drug ETF (520880) rose over 2% during trading, recovering above the 20-day moving average [1][7] Group 2: Industry Trends - The total transaction scale for China's innovative drug license-out reached a record $135.7 billion in 2025, with significant collaborations in January 2026, including a $18.5 billion deal between CSPC and AstraZeneca, and a $5.6 billion deal between Rongchang and AbbVie, highlighting the global value of domestic innovative drug pipelines [9] - The innovative drug sector is transitioning from "scale accumulation" to "value release," with a focus on commercial realization of pipeline expectations [9] - The innovative drug sector has seen a correction over the past two quarters, but many quality stocks now offer attractive valuations, suggesting increased attention is warranted [9] Group 3: Investment Recommendations - Analysts recommend focusing on high-growth and improving expectation sectors within the pharmaceutical industry, as the impact of medical insurance cost control has been fully reflected [11] - The Hong Kong Stock Connect Innovation Drug ETF (520880) and its associated funds are highlighted for their 100% focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [11] - The Hong Kong Stock Connect Medical ETF (159137) is suggested for its coverage of innovative medical concepts, including brain-computer interfaces and AI healthcare, while also encompassing leading companies across the entire innovative drug supply chain [11]

Core Viewpoint - The Hong Kong stock market showed strong performance in the early session, particularly in the innovative drug sector, indicating a robust demand for pharmaceuticals and a shift towards an "innovation-driven" revenue era in the industry [1] Group 1: Market Performance - Innovative drug stocks performed well, with notable gains: Zai Lab rose over 6%, CanSino Biologics-B increased over 5%, and Rongchang Biologics climbed over 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose over 2%, reflecting the positive sentiment in the sector [1] Group 2: Industry Insights - Analysts attribute the pharmaceutical industry's ability to reach new highs despite ongoing challenges to the continuous demand for medical solutions and the increasing number of unmet needs [1] - Pharmaceutical companies are significantly increasing their R&D investments to address these unmet needs, positioning China as a key player in global innovative drug development [1] - The trend of overseas licensing has been rising year after year, further emphasizing the industry's shift towards innovation [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the performance characteristics of listed companies in the innovative drug sector [1] - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]

Group 1 - The core viewpoint of the articles indicates that the recent volatility in Hong Kong's technology sector, with the Hang Seng Tech Index dropping 6.5% in a week, is primarily due to liquidity shocks, but the outlook for investing in Hong Kong tech stocks remains positive with high odds and win rates [1] - From the perspective of odds, the discount of Hong Kong tech stocks relative to A-share tech stocks is near historical lows, suggesting significant undervaluation, especially in the context of improved regulatory and economic conditions compared to 2022 and 2023 [1] - In terms of win rates, favorable factors are accumulating, including the peak of overseas liquidity shocks having passed, the effectiveness of the "buy the dip" strategy, and the potential for a rebound as the relative valuation of Hong Kong tech stocks approaches historical lows [1] Group 2 - Investment opportunities in Hong Kong tech-related ETFs are highlighted, including the Hang Seng Tech Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and Hong Kong Stock Connect Tech ETF (159101.SZ), which provide low-threshold access for A-share investors [2] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet companies such as Alibaba, Baidu, Tencent, and NetEase, while the Hong Kong Stock Connect Tech ETF (159101.SZ) emphasizes leading companies and includes innovative pharmaceutical stocks [2] - These ETFs are listed on mainland stock exchanges and support T+0 intraday trading, offering convenience for investors without the need for cross-border accounts or currency exchange [2]

Market Overview - On February 9, Hong Kong stocks followed the positive trend of global markets, with the Hang Seng Index rising by 467 points (1.7%) to close at 27,027 points[1] - The Hang Seng Tech Index increased by 71 points (1.3%), closing at 5,417 points, with total market turnover reaching HKD 255.1 billion[1] - Southbound capital recorded a net outflow of HKD 1.89 billion[1] Insurance Sector - In January, the new premium scale for 79 life insurance companies through bancassurance channels increased by 27.6% year-on-year[1] - China Life (2628 HK) and Ping An (2318 HK) saw their stock prices rise by 4% and 4.9%, respectively[1] - Other insurance stocks like China Taiping (966 HK), PICC (1339 HK), and China Pacific Insurance (2328 HK) increased by 3.5%-4%[1] Precious Metals - Precious metal prices rebounded, leading to stock increases for China Gold International (2099 HK), Zhaojin Mining (1818 HK), and Zijin Mining (2899 HK), which rose by 4.5%-5.6%[1] U.S. Market Insights - The U.S. economy is expected to see a slight decline in employment numbers, with the market anticipating an addition of 69,000 jobs and an unemployment rate holding steady at 4.4%[2] - The Dow Jones Index closed slightly higher, up 20 points (0.04%) at 50,135 points, while the Nasdaq and S&P 500 indices rose by 207 points (0.9%) and 32 points, respectively[2] Automotive Sector - Minth Group (425 HK) announced a joint venture with Gree Harmonic (688017 CH) in the U.S. for humanoid robot joint module design, resulting in a 7.5% stock increase[3] - Other automotive stocks like Xpeng Motors (9868 HK) and Seres (9927 HK) rose by 2.7%-2.9%, while NIO (9866 HK) fell by 0.5%[3] Pharmaceutical Developments - The Hang Seng Healthcare Index rose by 2.1%, with Innovent Biologics (1801 HK) announcing a strategic partnership with Eli Lilly (LLY US) for global R&D in oncology and immunology[3] - Innovent will receive an upfront payment of USD 350 million and could earn up to USD 8.5 billion in milestone payments[3]